Skip to main content
Monique Andersson on Muck Rack

Monique Andersson

As seen in: Nature, Wiley Online Library, BMJ Open, The BMJ, The Conversation, BMC Global and Public Health, The Lancet, AllAfrica
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Monique

Contact Monique, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Gonorrhoea: rising cases and antimicrobial resistance

|
By Peter Davis, Eloise Williams, Monique Andersson, Odile B Harrison
| The BMJ Verified
Peter Davis, infectious diseases and microbiology specialist registrar1 2, Eloise Williams, clinical microbiologist and infectious diseases physician3 4, Monique I Andersson, consultant in clinical infection, associate professor25, Odile B Harrison, research fellow6, Susanne H Hodgson, consultant physician in infectious diseases and microbiology and clinician scientist1 1The Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK 2Department of Microbiology, Oxford...
Open in Who Shared Issue with article?

Author Correction: The plasmidome associated with Gram-negative bloodstream infections: a large-scale observational study using complete plasmid assemblies | Nature Communications

|
By Samuel Lipworth, William Matlock, Liam Shaw, Karina-Doris Vihta, James Kavanagh, Monique Andersson, Katie Jeffery
| Nature Verified
Correction to: Nature Communications https://doi.org/10.1038/s41467-024-45761-7, published online 22 February 2024 In this article the author name William Matlock was incorrectly written as Willam Matlock. The original article has been corrected.
Open in Who Shared View Duplicates (5) Issue with article?

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients - Nature Communications

|
By Joseph F Standing, Laura Buggiotti, Claire Smith, Theo Sanderson, Fiona Ashford, Adrian Shields, Jienchi Dorward, Duncan Richards, Najib M. Rahman, Ly-Mee Yu, Nigel Hart, Philip Evans, Monique Andersson, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Saye Khoo, Christopher Butler, David Lowe, Judith Breuer
| Nature Verified
Abstract Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 324) were recruited to study viral and antibody dynamics and the effect of molnupiravir on viral whole genome sequence from 1437 viral genomes. Molnupiravir accelerates viral load decline, but virus is detectable by Day 5 in most cases.
Open in Who Shared Issue with article?
See all 14 licensed articles (15 Total)